A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
observed in 3 patients (25%). There was no response in 2 patients (16%). The overall response rate at 4 weeks was 83%. Infectious complications were common, including bacteremia (41%), adenovirus viremia (50%), and CMV viremia (33%). Relapse of acute GVHD was observed in 42% of complete responders. Fifty percent of patients are currently surviving at a median follow up time of 775 days following first alemtuzumab course. We conclude that alemtuzumab is an effective treatment for steroiddoi:10.1016/j.bbmt.2011.12.434 fatcat:ns4uep3x7zhfronuoql76uhhqu